The paper presents a novel approach to prediction of the combined therapy outcome for non-small lung cancer patients. A hybrid model is proposed, consisting of two parts. The first one is a mathematical model of tumor response to therapy, whose parameters are estimated by a neural network based regressor, constituting the second component of the hybrid model. Estimation is based on data from mass spectrometry of patient blood plasma samples. Comparison of clinical and simulation-based survival curves is used to evaluate the quality of the model.
EN
The paper presents a novel approach to the prediction of the combined therapy outcome for non-small lung cancer patients. A hybrid model is proposed, consisting of two parts. The first one is a mathematical model of tumor response to therapy, whose parameters are expressed as linear function of data from massspectrometry of patient blood plasma samples. These linear functions constitute thesecond component of the hybrid model. A comparison of clinical and simulation-based survival curves is used to evaluate the quality of the model.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.